ERBB2 and breast carcinoma: The third gene, COL10A1, has been widely reported to be a oncogene in multiple cancer types [32], contribute to vasculature, and also used as biomarker for neo-adjuvant therapy effect prediction indicator in ER+/HER2+ breast cancer [33].